Previous close | 1.5250 |
Open | 1.5300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 1.5000 - 1.5300 |
52-week range | 1.4300 - 6.7900 |
Volume | |
Avg. volume | 4,577 |
Market cap | 29.928M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6300 |
Earnings date | 14 Jun 2022 - 20 Jun 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in an interview with TMX Group.
Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals Inc., ("Medexus" or the "Company") (TSX: MDP), and his team joined Daniel Lubienietzky, Manager, Life Sciences, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.